Zimbabwe - anglais - Medicines Control Authority

janssen-cilag international nv - etravirine - tablet; oral - 100mg

Zimbabwe - anglais - Medicines Control Authority

janssen-cilag international - etravirine - tablet; oral - 25 mg

Arabie saoudite - anglais - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag, belgium - etravirine - tablet - 100 mg

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

janssen-cilag international nv, belgium - etravirine - tablets - 100 mg

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

janssen-cilag international nv, belgium - etravirine - tablets - 25mg

Ouganda - anglais - National Drug Authority

janssen-cilag international nv - etravirine - oral solid ordinary tablets - 25mg

Ouganda - anglais - National Drug Authority

janssen-cilag international nv - etravirine - oral solid ordinary tablets - 100mg

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

janssen pharmaceutical k.k. - etravirine - white to slightly-yellowish white tablet, major axis 19 mm, minor axis 9.5 mm, thickness 6.6 mm

Singapour - anglais - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg

Israël - anglais - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; dolutegravir as sodium; lamivudine - film coated tablets - dolutegravir as sodium 50 mg; abacavir as sulfate 600 mg; lamivudine 300 mg - lamivudine and abacavir and dolutegravir - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents above 12 years of age weighing at least 40 kg.before initiating treatment with abacavir-containing products, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.